A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension

The Lancet

Volumn 388, Issue 10060, 2016, Pages 2665-2712

  Olsen, Michael H ^a,b   Angell, Sonia Y ^c   Asma, Samira ^d   Boutouyrie, Pierre ^e   Burger, Dylan ^f   Chirinos, Julio A ^g   Damasceno, Albertino ^h   Delles, Christian ⁱ   Gimenez Roqueplo, Anne Paule ^e,j,k   Hering, Dagmara ^l   López Jaramillo, Patricio ^m   Martinez, Fernando ⁿ   Perkovic, Vlado ^o   Rietzschel, Ernst R ^p   Schillaci, Giuseppe ^q   Schutte, Aletta E ^b   Scuteri, Angelo ^r   Sharman, James E ^s   Wachtell, Kristian ^t   Wang, Ji Guang ^u  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NORTH WEST UNIVERSITY   (South Africa)

^c NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g Department of Medicine at University Hospital of Pennsylvania and Veteran's Administration ^*  (United States)

^h EDUARDO MONDLANE UNIVERSITY   (Mozambique)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^m UNIVERSIDAD DE SANTANDER   (Colombia)

ⁿ UNIVERSITY OF VALENCIA   (Spain)

^o UNIVERSITY OF SYDNEY   (Australia)

^p GHENT UNIVERSITY HOSPITAL   (Belgium)

^q UNIVERSITY OF PERUGIA   (Italy)

^r TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^s UNIVERSITY OF TASMANIA   (Australia)

^t OSLO UNIVERSITY HOSPITAL   (Norway)

^u SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

AGE; AGING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CULTURAL ANTHROPOLOGY; ELEVATED BLOOD PRESSURE; EMPOWERMENT; ENVIRONMENTAL CHANGE; ETHNIC DIFFERENCE; EVIDENCE BASED PRACTICE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH LITERACY; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MATERNAL WELFARE; MEDICAL TECHNOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIMARY PREVENTION; PRIMORDIAL PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY PREVENTION; SELF CARE; SELF MONITORING; SLEEP DISORDERED BREATHING; SOCIAL MEDIA; SODIUM RESTRICTION; VASCULAR DISEASE; BLOOD PRESSURE; GLOBAL DISEASE BURDEN; GLOBAL HEALTH; PRACTICE GUIDELINE;

BLOOD PRESSURE; GLOBAL BURDEN OF DISEASE; GLOBAL HEALTH; GUIDELINES AS TOPIC; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 84994447926     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31134-5     Document Type: Review

References (473)

1. 1 Mancia, G, Fagard, R, Narkiewicz, K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
2. 2 Tunstall-Pedoe, H, Connaghan, J, Woodward, M, Tolonen, H, Kuulasmaa, K, Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-1990s, and the role of medication. BMJ 332 (2006), 629–635.
3. 3 Danaei, G, Finucane, MM, Lin, JK, et al., the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet 377 (2011), 568–577.
4. 4 Mills, KT, Bundy, JD, Kelly, TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134 (2016), 441–450.
5. 5 Stampfer, MJ, Hu, FB, Manson, JE, Rimm, EB, Willett, WC, Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 343 (2000), 16–22.
6. 6 Hoevenaar-Blom, MP, Spijkerman, AM, Kromhout, D, Verschuren, WM, Sufficient sleep duration contributes to lower cardiovascular disease risk in addition to four traditional lifestyle factors: the MORGEN study. Eur J Prev Cardiol 21 (2014), 1367–1375.
7. 7 Raitakari, OT, Juonala, M, Kähönen, M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 290 (2003), 2277–2283.
8. 8 Aatola, H, Hutri-Kähönen, N, Juonala, M, et al. Lifetime risk factors and arterial pulse wave velocity in adulthood: the cardiovascular risk in young Finns study. Hypertension 55 (2010), 806–811.
9. 9 Oikonen, M, Nuotio, J, Magnussen, CG, et al. Repeated blood pressure measurements in childhood in prediction of hypertension in adulthood. Hypertension 67 (2016), 41–47.
10. 10 Pälve, KS, Pahkala, K, Magnussen, CG, et al. Association of physical activity in childhood and early adulthood with carotid artery elasticity 21 years later: the cardiovascular risk in Young Finns Study. J Am Heart Assoc, 3, 2014, e000594.
11. 11 Ferreira, I, van de Laar, RJ, Prins, MH, Twisk, JW, Stehouwer, CD, Carotid stiffness in young adults: a life-course analysis of its early determinants: the Amsterdam Growth and Health Longitudinal Study. Hypertension 59 (2012), 54–61.
12. 12 Liu, K, Daviglus, ML, Loria, CM, et al. Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study. Circulation 125 (2012), 996–1004.
13. 13 Ehret, GB, Munroe, PB, Rice, KM, et al. the International Consortium for Blood Pressure Genome-Wide Association Studies the CARDIoGRAM consortium the CKDGen Consortium the KidneyGen Consortium the EchoGen consortium, the CHARGE-HF consortium. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478 (2011), 103–109.
14. 14 Ference, BA, Julius, S, Mahajan, N, Levy, PD, Williams, KAS Sr, Flack, JM, Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension 63 (2014), 1182–1188.
15. 15 Lonn, EM, Bosch, J, Lopez-Jaramillo, P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
16. 16 Mente, A, O'Donnell, M, Rangarajan, S, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet, 2016, 10.1016/S0140-6736(16)30467-6 published online May 20.
17. 17 Scuteri, A, Lattanzio, F, Bernabei, R, The life-course approach to chronic disease: the active and healthy ageing view/perspective. J Am Geriatr Soc, 2016, 10.1111/jgs.14271 published online July 26.
18. 18 WHO. A global brief on hypertension: silent killer, global public health crisis. http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/, 2013 (accessed Dec 28, 2015).
19. 19 Kearney, PM, Whelton, M, Reynolds, K, Muntner, P, Whelton, PK, He, J, Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005), 217–223.
20. 20 Lim, SS, Vos, T, Flaxman, AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2224–2260.
21. 21 Whelton, PK, He, J, Appel, LJ, et al., the National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 288 (2002), 1882–1888.
22. 22 Andersson, OK, Almgren, T, Persson, B, Samuelsson, O, Hedner, T, Wilhelmsen, L, Survival in treated hypertension: follow up study after two decades. BMJ 317 (1998), 167–171.
23. 23 Poulter, NR, Prabhakaran, D, Caulfield, M, Hypertension. Lancet 386 (2015), 801–812.
24. 24 Kannel, WB, Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275 (1996), 1571–1576.
25. 25 World Bank, WHO. Tracking universal health coverage: first global monitoring report. http://reliefweb.int/report/world/tracking-universal-health-coverage-first-global-monitoring-report, 2015 (accessed March 10, 2016).
26. 26 Lewington, S, Clarke, R, Qizilbash, N, Peto, R, Collins, R, the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
27. 27 Xie, X, Atkins, E, Lv, J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2015), 435–443.
28. 28 Blacher, J, Evans, A, Arveiler, D, et al., the PRIME Study Group. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens 24 (2010), 19–26.
29. 29 Lawes, CM, Vander Hoorn, S, Law, MR, Elliott, P, MacMahon, S, Rodgers, A, Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 24 (2006), 423–430.
30. 30 Asayama, K, Satoh, M, Murakami, Y, et al., the Evidence for Cardiovascular Prevention From Observational Cohorts in Japan (EPOCH-JAPAN) Research Group. Cardiovascular risk with and without antihypertensive drug treatment in the Japanese general population: participant-level meta-analysis. Hypertension 63 (2014), 1189–1197.
31. 31 Britt, H, Miller, G, Charles, J, et al. General practice activity in Australia 2009–10. http://www.aihw.gov.au/publication-detail/?id=6442472433, 2010 (accessed Dec 28, 2015).
32. 32 Briganti, EM, Shaw, JE, Chadban, SJ, et al. the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 179 (2003), 135–139.
33. 33 Chow, CK, Teo, KK, Rangarajan, S, et al., the PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
34. 34 Olsen, MH, Spencer, S, A global perspective on hypertension: a Lancet Commission. Lancet 386 (2015), 637–638.
35. 35 Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
36. 36 United Nations Department of Economic and Social Affairs, Population Division. World population prospects, the 2015 revision. http://esa.un.org/unpd/wpp/, 2015 (accessed May 10, 2016).
37. 37 Odden, MC, Coxson, PG, Moran, A, Lightwood, JM, Goldman, L, Bibbins-Domingo, K, The impact of the aging population on coronary heart disease in the United States. Am J Med, 124, 2011, 827 33.e5.
38. 38 MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304 (1992), 405–412.
39. 39 Wright, JT Jr, Williamson, JD, Whelton, PK, et al., the SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
40. 40 Williamson, JD, Supiano, MA, Applegate, WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA 315 (2016), 2673–2682.
41. 41 The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
42. 42 Beckett, NS, Peters, R, Fletcher, AE, et al., the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008), 1887–1898.
43. 43 le Noble, JL, Tangelder, GJ, Slaaf, DW, van Essen, H, Reneman, RS, Struyker-Boudier, HA, A functional morphometric study of the cremaster muscle microcirculation in young spontaneously hypertensive rats. J Hypertens 8 (1990), 741–748.
44. 44 Pladys, P, Sennlaub, F, Brault, S, et al. Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero. Am J Physiol Regul Integr Comp Physiol 289 (2005), R1580–R1588.
45. 45 Landau, J, Davis, E, Capillary thinning and high capillary blood-pressure in hypertension. Lancet 272 (1957), 1327–1330.
46. 46 Montezano, AC, Dulak-Lis, M, Tsiropoulou, S, Harvey, A, Briones, AM, Touyz, RM, Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol 31 (2015), 631–641.
47. 47 Kaess, BM, Rong, J, Larson, MG, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 308 (2012), 875–881.
48. 48 Laurent, S, Boutouyrie, P, The structural factor of hypertension: large and small artery alterations. Circ Res 116 (2015), 1007–1021.
49. 49 Nilsson, PM, Boutouyrie, P, Laurent, S, Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension 54 (2009), 3–10.
50. 50 Vlachopoulos, C, Aznaouridis, K, O'Rourke, MF, Safar, ME, Baou, K, Stefanadis, C, Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 31 (2010), 1865–1871.
51. 51 Ben-Shlomo, Y, Spears, M, Boustred, C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63 (2014), 636–646.
52. 52 O'Rourke, MF, Safar, ME, Dzau, V, The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature. Vasc Med 15 (2010), 461–468.
53. 53 James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
54. 54 National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guidelines [CG127]. https://www.nice.org.uk/guidance/cg127, 2011 (accessed Dec 28, 2015).
55. 55 Fok, H, Cruickshank, JK, Future treatment of hypertension: shifting the focus from blood pressure lowering to arterial stiffness modulation?. Curr Hypertens Rep, 17, 2015, 67.
56. 56 Ibrahim, MM, Damasceno, A, Hypertension in developing countries. Lancet 380 (2012), 611–619.
57. 57 Gillespie, CD, Kuklin, EV, Briss, PA, Blair, NA, Hong, Y, Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 60 (2011), 103–108.
58. 58 Nwankwo, T, Yoon, SS, Burt, V, Gu, Q, Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS data brief, no 133, 2013, National Center for Health Statistics, Hyattsville, MD.
59. 59 Gillespie, CD, Hurvitz, KA, Prevalence of hypertension and controlled hypertension—United States, 2007–2010. MMWR Morb Mortal Wkly Rep 62 (2013), 144–148.
60. 60 Yoon, SS, Burt, V, Louis, T, Carroll, MD, Hypertension among adults in the United States, 2009–2010. NCHS data brief, no 107, 2012, National Center for Health Statistics, Hyattsville, MD.
61. 61 New York City Department of Health and Mental Hygiene. Epiquery: NYC interactive health data system—community health survey. https://a816-healthpsi.nyc.gov/epiquery/, 2013 (accessed March 11, 2016).
62. 62 Angell, SY, Garg, RK, Gwynn, RC, Bash, L, Thorpe, LE, Frieden, TR, Prevalence, awareness, treatment, and predictors of control of hypertension in New York City. Circ Cardiovasc Qual Outcomes 1 (2008), 46–53.
63. 63 Office of Disease Prevention and Health Promotion. Social determinants of health. https://www.healthypeople.gov/2020/topics-objectives/topic/social-determinants-of-health, 2011 (accessed March 13, 2016).
64. 64 Danaei, G, Singh, GM, Paciorek, CJ, et al. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation 127 (2013), 1493–1502 1502.e1–8.
65. 65 GBD 2013 Risk Factors Collaborators, Forouzanfar, MH, Alexander, L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 2287–2323.
66. 66 Falaschetti, E, Mindell, J, Knott, C, Poulter, N, Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383 (2014), 1912–1919.
67. 67 Rodgers, A, Ezzati, M, Vander Hoorn, S, Lopez, AD, Lin, RB, Murray, CJ, the Comparative Risk Assessment Collaborating Group. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med, 1, 2004, e27.
68. 68 WHO. Global status report on noncommunicable diseases 2010. http://www.who.int/nmh/publications/ncd_report2010/en/, 2011 (accessed Dec 28, 2015).
69. 69 World Economic Forum. The global economic burden of non-communicable diseases. http://www.weforum.org/reports/global-economic-burden-non-communicable-diseases, 2011 (accessed Dec 28, 2015).
70. 70 Weber, MA, Schiffrin, EL, White, WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32 (2014), 3–15.
71. 71 Kotseva, K, De Bacquer, D, Jennings, C, et al., the EUROASPIRE Investigators. Adverse lifestyle trends counter improvements in cardiovascular risk factor management in coronary patients. J Am Coll Cardiol 66 (2015), 1634–1636.
72. 72 Lawes, CM, Vander Hoorn, S, Rodgers, A, the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371 (2008), 1513–1518.
73. 73 United Nations. Sustainable development goals. Transforming our world—the 2030 agenda for sustainable development. https://sustainabledevelopment.un.org/?menu=1300, 2015 (accessed Dec 28, 2015).
74. 74 WHO. Global status report on noncommunicable diseases. http://www.who.int/nmh/publications/ncd-status-report-2014/en/, 2014 (accessed Dec 28, 2015).
75. 75 Donaldson, EA, Waters, HR, Arora, M, Varghese, B, Dave, P, Modi, B, A cost-effectiveness analysis of India's 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health 8 (2011), 1271–1286.
76. 76 Gaudreau, K, Sanford, CJ, Cheverie, C, McClure, C, The effect of a smoking ban on hospitalization rates for cardiovascular and respiratory conditions in Prince Edward Island, Canada. PLoS One, 8, 2013, e56102.
77. 77 Gortmaker, SL, Swinburn, BA, Levy, D, et al. Changing the future of obesity: science, policy, and action. Lancet 378 (2011), 838–847.
78. 78 Roberto, CA, Swinburn, B, Hawkes, C, et al. Patchy progress on obesity prevention: emerging examples, entrenched barriers, and new thinking. Lancet 385 (2015), 2400–2409.
79. 79 Krug, EG, Trends in diabetes: sounding the alarm. Lancet 387 (2016), 1485–1486.
80. 80 NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387 (2016), 1377–1396.
81. 81 Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol 2 (2014), 634–647.
82. 82 Crino, M, Sacks, G, Vandevijvere, S, Swinburn, B, Neal, B, The influence on population weight gain and obesity of the macronutrient composition and energy density of the food supply. Curr Obes Rep 4 (2015), 1–10.
83. 83 Nanditha, A, Ma, RC, Ramachandran, A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care 39 (2016), 472–485.
84. 84 Sofi, F, Abbate, R, Gensini, GF, Casini, A, Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 92 (2010), 1189–1196.
85. 85 Domenech, M, Roman, P, Lapetra, J, et al. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. Hypertension 64 (2014), 69–76.
86. 86 Estruch, R, Ros, E, Salas-Salvadó, J, et al., the PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (2013), 1279–1290.
87. 87 Appel, LJ, Brands, MW, Daniels, SR, Karanja, N, Elmer, PJ, Sacks, FM, the American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 47 (2006), 296–308.
88. 88 Appel, LJ, Moore, TJ, Obarzanek, E, et al., the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 336 (1997), 1117–1124.
89. 89 Cook, NR, Appel, LJ, Whelton, PK, Lower levels of sodium intake and reduced cardiovascular risk. Circulation 129 (2014), 981–989.
90. 90 Mente, A, O'Donnell, MJ, Rangarajan, S, et al., the PURE Investigators. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med 371 (2014), 601–611.
91. 91 Adrogue, HJ, Madias, NE, Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 356 (2007), 1966–1978.
92. 92 Kapil, V, Khambata, RS, Robertson, A, Caulfield, MJ, Ahluwalia, A, Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension 65 (2015), 320–327.
93. 93 Siervo, M, Lara, J, Ogbonmwan, I, Mathers, JC, Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr 143 (2013), 818–826.
94. 94 Lidder, S, Webb, AJ, Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway. Br J Clin Pharmacol 75 (2013), 677–696.
95. 95 Nocon, M, Hiemann, T, Müller-Riemenschneider, F, Thalau, F, Roll, S, Willich, SN, Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 15 (2008), 239–246.
96. 96 Parker, ED, Schmitz, KH, Jacobs, DR Jr, Dengel, DR, Schreiner, PJ, Physical activity in young adults and incident hypertension over 15 years of follow-up: the CARDIA study. Am J Public Health 97 (2007), 703–709.
97. 97 Huai, P, Xun, H, Reilly, KH, Wang, Y, Ma, W, Xi, B, Physical activity and risk of hypertension: a meta-analysis of prospective cohort studies. Hypertension 62 (2013), 1021–1026.
98. 98 Diaz, KM, Shimbo, D, Physical activity and the prevention of hypertension. Curr Hypertens Rep 15 (2013), 659–668.
99. 99 Berry, JD, Willis, B, Gupta, S, et al. Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men: the Cooper Center Longitudinal Study. J Am Coll Cardiol 57 (2011), 1604–1610.
100. 100 Neter, JE, Stam, BE, Kok, FJ, Grobbee, DE, Geleijnse, JM, Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42 (2003), 878–884.
101. 101 Stevens, VJ, Obarzanek, E, Cook, NR, et al., the Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 134 (2001), 1–11.
102. 102 Caterson, ID, Finer, N, Coutinho, W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 14 (2012), 523–530.
103. 103 Lightwood, JM, Glantz, SA, Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation 120 (2009), 1373–1379.
104. 104 Celermajer, DS, Sorensen, KE, Georgakopoulos, D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88 (1993), 2149–2155.
105. 105 Ronksley, PE, Brien, SE, Turner, BJ, Mukamal, KJ, Ghali, WA, Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ, 342, 2011, d671.
106. 106 Briasoulis, A, Agarwal, V, Messerli, FH, Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 14 (2012), 792–798.
107. 107 Zatu, MC, Van Rooyen, JM, Kruger, A, Schutte, AE, Alcohol intake, hypertension development and mortality in black South Africans. Eur J Prev Cardiol 23 (2016), 308–315.
108. 108 Rainforth, MV, Schneider, RH, Nidich, SI, Gaylord-King, C, Salerno, JW, Anderson, JW, Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. Curr Hypertens Rep 9 (2007), 520–528.
109. 109 Park, J, Lyles, RH, Bauer-Wu, S, Mindfulness meditation lowers muscle sympathetic nerve activity and blood pressure in African-American males with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 307 (2014), R93–101.
110. 110 Knowler, WC, Barrett-Connor, E, Fowler, SE, et al., the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
111. 111 Hinderliter, AL, Sherwood, A, Craighead, LW, et al. The long-term effects of lifestyle change on blood pressure: one-year follow-up of the ENCORE study. Am J Hypertens 27 (2014), 734–741.
112. 112 Chow, CK, Redfern, J, Hillis, GS, et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. JAMA 314 (2015), 1255–1263.
113. 113 Thakkar, J, Kurup, R, Laba, TL, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med 176 (2016), 340–349.
114. 114 Glanz, K, Bishop, DB, The role of behavioral science theory in development and implementation of public health interventions. Annu Rev Public Health 31 (2010), 399–418.
115. 115 Kullo, IJ, Jouni, H, Olson, JE, Montori, VM, Bailey, KR, Design of a randomized controlled trial of disclosing genomic risk of coronary heart disease: the Myocardial Infarction Genes (MI-GENES) study. BMC Med Genomics, 8, 2015, 51.
116. 116 Swinburn, BA, Sacks, G, Hall, KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 378 (2011), 804–814.
117. 117 Lloyd-Sherlock, P, Beard, J, Minicuci, N, Ebrahim, S, Chatterji, S, Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol 43 (2014), 116–128.
118. 118 Schutte, AE, Schutte, R, Huisman, HW, et al. Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in black South Africans? A 5-year prospective study. Int J Epidemiol 41 (2012), 1114–1123.
119. 119 Artinian, NT, Fletcher, GF, Mozaffarian, D, et al., the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 122 (2010), 406–441.
120. 120 Larsson, SC, Akesson, A, Wolk, A, Healthy diet and lifestyle and risk of stroke in a prospective cohort of women. Neurology 83 (2014), 1699–1704.
121. 121 Piepoli, MF, Hoes, AW, Agewall, S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol, 2016, 10.1093/eurheartj/ehw106 published online May 23.
122. 122 Eckel, RH, Jakicic, JM, Ard, JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2960–2984.
123. 123 Arena, R, Guazzi, M, Lianov, L, et al. the AHA Writing Group the ESC/EACPR Writing Group, the ACPM Writing Group. Healthy lifestyle interventions to combat noncommunicable disease-a novel nonhierarchical connectivity model for key stakeholders: a policy statement from the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and American College of Preventive Medicine. Eur Heart J 36 (2015), 2097–2109.
124. 124 WHO. School and youth health. http://www.who.int/school_youth_health/en, 2016 (accessed March 13, 2016).
125. 125 Taylor, MJ, McCormick, D, Shawis, T, Impson, R, Griffin, M, Activity-promoting gaming systems in exercise and rehabilitation. J Rehabil Res Dev 48 (2011), 1171–1186.
126. 126 Siegfried, N, Pienaar, DC, Ataguba, JE, et al. Restricting or banning alcohol advertising to reduce alcohol consumption in adults and adolescents. Cochrane Database Syst Rev, 11, 2014 CD010704.
127. 127 Hofman, KJ, Tollman, SM, Population health in South Africa: a view from the salt mines. Lancet Glob Health 1 (2013), e66–e67.
128. 128 Harris, JL, Bargh, JA, Television viewing and unhealthy diet: implications for children and media interventions. Health Commun 24 (2009), 660–673.
129. 129 Torjesen, I, BMA calls for 20% sugar tax to subsidise cost of fruit and vegetables. BMJ, 351, 2015, h3803.
130. 130 Stafford, N, Denmark cancels “fat tax” and shelves “sugar tax” because of threat of job losses. BMJ, 345, 2012, e7889.
131. 131 Anand, SS, Yusuf, S, Vuksan, V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 356 (2000), 279–284.
132. 132 Scuteri, A, Laurent, S, Cucca, F, et al., the Metabolic Syndrome and Arteries Research (MARE) Consortium. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol 22 (2015), 486–491.
133. 133 Nilsson, PM, Boutouyrie, P, Cunha, P, et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens 31 (2013), 1517–1526.
134. 134 Gorelick, PB, Scuteri, A, Black, SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 (2011), 2672–2713.
135. 135 Mozaffarian, D, Fahimi, S, Singh, GM, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 371 (2014), 624–634.
136. 136 Trieu, K, Neal, B, Hawkes, C, et al. Salt reduction initiatives around the world: a systematic review of progress towards the global target. PLoS One, 10, 2015, e0130247.
137. 137 Adler, AJ, Taylor, F, Martin, N, Gottlieb, S, Taylor, RS, Ebrahim, S, Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev, 18, 2014 CD009217.
138. 138 Sacks, FM, Svetkey, LP, Vollmer, WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344 (2001), 3–10.
139. 139 Aburto, NJ, Ziolkovska, A, Hooper, L, Elliott, P, Cappuccio, FP, Meerpohl, JJ, Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ, 346, 2013, f1326.
140. 140 He, FJ, Li, J, Macgregor, GA, Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev, 4, 2013 CD004937.
141. 141 O'Donnell, M, Mente, A, Rangarajan, S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 371 (2014), 612–623.
142. 142 O'Donnell, MJ, Yusuf, S, Mente, A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 306 (2011), 2229–2238.
143. 143 Stolarz-Skrzypek, K, Kuznetsova, T, Thijs, L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 305 (2011), 1777–1785.
144. 144 He, FJ, Pombo-Rodrigues, S, Macgregor, GA, Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open, 4, 2014, e004549.
145. 145 Barker, DJ, Bull, AR, Osmond, C, Simmonds, SJ, Fetal and placental size and risk of hypertension in adult life. BMJ 301 (1990), 259–262.
146. 146 Curhan, GC, Chertow, GM, Willett, WC, et al. Birth weight and adult hypertension and obesity in women. Circulation 94 (1996), 1310–1315.
147. 147 Curhan, GC, Willett, WC, Rimm, EB, Spiegelman, D, Ascherio, AL, Stampfer, MJ, Birth weight and adult hypertension, diabetes mellitus, and obesity in US men. Circulation 94 (1996), 3246–3250.
148. 148 Manalich, R, Reyes, L, Herrera, M, Melendi, C, Fundora, I, Relationship between weight at birth and the number and size of renal glomeruli in humans: a histomorphometric study. Kidney Int 58 (2000), 770–773.
149. 149 Hughson, M, Farris, AB 3rd, Douglas-Denton, R, Hoy, WE, Bertram, JF, Glomerular number and size in autopsy kidneys: the relationship to birth weight. Kidney Int 63 (2003), 2113–2122.
150. 150 Leeson, CP, Kattenhorn, M, Morley, R, Lucas, A, Deanfield, JE, Impact of low birth weight and cardiovascular risk factors on endothelial function in early adult life. Circulation 103 (2001), 1264–1268.
151. 151 Ikeda, N, Gakidou, E, Hasegawa, T, Murray, CJ, Understanding the decline of mean systolic blood pressure in Japan: an analysis of pooled data from the National Nutrition Survey, 1986–2002. Bull World Health Organ 86 (2008), 978–988.
152. 152 Goff, DC, Howard, G, Russell, GB, Labarthe, DR, Birth cohort evidence of population influences on blood pressure in the United States, 1887–1994. Ann Epidemiol 11 (2001), 271–279.
153. 153 McCarron, P, Smith, GD, Okasha, M, Secular changes in blood pressure in childhood, adolescence and young adulthood: systematic review of trends from 1948 to 1998. J Hum Hypertens 16 (2002), 677–689.
154. 154 Scherrer, U, Rimoldi, SF, Sartori, C, Messerli, FH, Rexhaj, E, Fetal programming and epigenetic mechanisms in arterial hypertension. Curr Opin Cardiol 30 (2015), 393–397.
155. 155 Lee, AC, Katz, J, Blencowe, H, et al., the CHERG SGA-Preterm Birth Working Group. National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Glob Health 1 (2013), e26–e36.
156. 156 Luyckx, VA, Brenner, BM, Birth weight, malnutrition and kidney-associated outcomes—a global concern. Nat Rev Nephrol 11 (2015), 135–149.
157. 157 Jensen, JD, Ronit, K, The EU pledge for responsible marketing of food and beverages to children: implementation in food companies. Eur J Clin Nutr 69 (2015), 896–901.
158. 158 Gaziano, TA, Abrahams-Gessel, S, Denman, CA, et al. An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in Bangladesh, Guatemala, Mexico, and South Africa: an observational study. Lancet Glob Health 3 (2015), e556–e563.
159. 159 Jamie Oliver for Chief Medical Officer?. Lancet, 365, 2005, 1282.
160. 160 Flego, A, Herbert, J, Gibbs, L, et al. Methods for the evaluation of the Jamie Oliver Ministry of Food program, Australia. BMC Public Health, 13, 2013, 411.
161. 161 Fujikawa, T, Tochikubo, O, Sugano, T, Umemura, S, Accuracy of the pulse delay time technique with triple cuff for objective indirect blood pressure measurement. J Hypertens 31 (2013), 278–286.
162. 162 Campbell, NR, Gelfer, M, Stergiou, GS, et al. A call to regulate manufacture and marketing of blood pressure devices and cuffs: a position statement from the World Hypertension League, International Society of Hypertension and Supporting Hypertension Organizations. J Clin Hypertens (Greenwich) 18 (2016), 378–380.
163. 163 Graves, JW, Bailey, KR, Sheps, SG, The changing distribution of arm circumferences in NHANES III and NHANES 2000 and its impact on the utility of the ‘standard adult’ blood pressure cuff. Blood Press Monit 8 (2003), 223–227.
164. 164 Ostchega, Y, Dillon, C, Carroll, M, Prineas, RJ, McDowell, M, US demographic trends in mid-arm circumference and recommended blood pressure cuffs: 1988–2002. J Hum Hypertens 19 (2005), 885–891.
165. 165 Zdrojewski, T, Kozicka-Kakol, K, Chwojnicki, K, Szpakowski, P, Konarski, R, Wyrzykowski, B, Arm circumference in adults in Poland as an important factor influencing the accuracy of blood pressure readings. Blood Press Monit 10 (2005), 73–77.
166. 166 Palatini, P, Benetti, E, Fania, C, Malipiero, G, Saladini, F, Rectangular cuffs may overestimate blood pressure in individuals with large conical arms. J Hypertens 30 (2012), 530–536.
167. 167 Fagard, RH, Cornelissen, VA, Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 25 (2007), 2193–2198.
168. 168 Stergiou, GS, Asayama, K, Thijs, L, et al., the International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension 63 (2014), 675–682.
169. 169 Hanninen, MR, Niiranen, TJ, Puukka, PJ, Mattila, AK, Jula, AM, Determinants of masked hypertension in the general population: the Finn-Home study. J Hypertens 29 (2011), 1880–1888.
170. 170 Bobrie, G, Chatellier, G, Genes, N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 291 (2004), 1342–1349.
171. 171 Franklin, SS, Thijs, L, Li, Y, et al., the International Database on Ambulatory blood pressure in Relation to Cardiovascular Outcomes Investigators. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 61 (2013), 964–971.
172. 172 Pierdomenico, SD, Cuccurullo, F, Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 24 (2011), 52–58.
173. 173 Stergiou, GS, Omboni, S, Parati, G, Home or ambulatory blood pressure monitoring for the diagnosis of hypertension?. J Hypertens 33 (2015), 1528–1530.
174. 174 Ward, AM, Takahashi, O, Stevens, R, Heneghan, C, Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 30 (2012), 449–456.
175. 175 Mancia, G, Facchetti, R, Bombelli, M, Grassi, G, Sega, R, Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 47 (2006), 846–853.
176. 176 Parati, G, Stergiou, GS, Asmar, R, et al., the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 24 (2010), 779–785.
177. 177 Daskalopoulou, SS, Khan, NA, Quinn, RR, et al., the Canadian Hypertension Education Program. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 28 (2012), 270–287.
178. 178 Imai, Y, Kario, K, Shimada, K, et al. The Japanese Society of Hypertension Guidelines for Self-monitoring of Blood Pressure at Home (Second Edition). Hypertens Res 35 (2012), 777–795.
179. 179 Sharman, JE, Howes, FS, Head, GA, et al. Home blood pressure monitoring: Australian Expert Consensus Statement. J Hypertens 33 (2015), 1721–1728.
180. 180 Myers, MG, Godwin, M, Dawes, M, Kiss, A, Tobe, SW, Kaczorowski, J, Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 55 (2010), 195–200.
181. 181 Armstrong, D, Matangi, M, Brouillard, D, Myers, MG, Automated office blood pressure—being alone and not location is what matters most. Blood Press Monit 20 (2015), 204–208.
182. 182 Myers, MG, Kaczorowski, J, Paterson, JM, Dolovich, L, Tu, K, Thresholds for diagnosing hypertension based on automated office blood pressure measurements and cardiovascular risk. Hypertension 66 (2015), 489–495.
183. 183 Verdecchia, P, Porcellati, C, Schillaci, G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 24 (1994), 793–801.
184. 184 Fagard, RH, Celis, H, Thijs, L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51 (2008), 55–61.
185. 185 Ishikawa, J, Shimizu, M, Sugiyama Edison, E, et al., the J-TOP (Japan Morning Surge-Target Organ Protection) Study Investigators Group. Assessment of the reductions in night-time blood pressure and dipping induced by antihypertensive medication using a home blood pressure monitor. J Hypertens 32 (2014), 82–89.
186. 186 Rothwell, PM, Howard, SC, Dolan, E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375 (2010), 895–905.
187. 187 Gao, S, Hendrie, HC, Wang, C, et al. Redefined blood pressure variability measure and its association with mortality in elderly primary care patients. Hypertension 64 (2014), 45–52.
188. 188 Zamani, P, Bluemke, DA, Jacobs, DR Jr, et al. Resistive and pulsatile arterial load as predictors of left ventricular mass and geometry: the multi-ethnic study of atherosclerosis. Hypertension 65 (2015), 85–92.
189. 189 Herbert, A, Cruickshank, JK, Laurent, S, Boutouyrie, P, the Reference Values for Arterial Measurements Collaboration. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J 35 (2014), 3122–3133.
190. 190 Pucci, G, Ranalli, MG, Battista, F, Schillaci, G, Effects of β-blockers with and without vasodilating properties on central blood pressure: systematic review and meta-analysis of randomized trials in hypertension. Hypertension 67 (2016), 316–324.
191. 191 Williams, B, Lacy, PS, Thom, SM, et al. the CAFE Investigators the Anglo-Scandinavian Cardiac Outcomes Trial Investigators, the CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006), 1213–1225.
192. 192 Boutouyrie, P, Achouba, A, Trunet, P, Laurent, S, the EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 55 (2010), 1314–1322.
193. 193 Asmar, RG, London, GM, O'Rourke, ME, Safar, ME, the REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 38 (2001), 922–926.
194. 194 Kollias, A, Lagou, S, Zeniodi, ME, Boubouchairopoulou, N, Stergiou, GS, Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. Hypertension 67 (2016), 183–190.
195. 195 Sharman, JE, Marwick, TH, Gilroy, D, Otahal, P, Abhayaratna, WP, Stowasser, M, the Value of Central Blood Pressure for GUIDing ManagEment of Hypertension Study Investigators. Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal findings of the BP GUIDE study. Hypertension 62 (2013), 1138–1145.
196. 196 Hulsen, HT, Nijdam, ME, Bos, WJ, et al. Spurious systolic hypertension in young adults; prevalence of high brachial systolic blood pressure and low central pressure and its determinants. J Hypertens 24 (2006), 1027–1032.
197. 197 O'Rourke, MF, Adji, A, Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens 31 (2013), 649–654.
198. 198 Kobayashi, S, Yano, M, Kohno, M, et al. Influence of aortic impedance on the development of pressure-overload left ventricular hypertrophy in rats. Circulation 94 (1996), 3362–3368.
199. 199 Gillebert, TC, Lew, WY, Influence of systolic pressure profile on rate of left ventricular pressure fall. Am J Physiol 261 (1991), H805–H813.
200. 200 Chirinos, JA, Segers, P, Rietzschel, ER, et al., the Asklepios Investigators. Early and late systolic wall stress differentially relate to myocardial contraction and relaxation in middle-aged adults: the Asklepios study. Hypertension 61 (2013), 296–303.
201. 201 Chirinos, JA, Segers, P, Gillebert, TC, et al., the Asklepios Investigators. Arterial properties as determinants of time-varying myocardial stress in humans. Hypertension 60 (2012), 64–70.
202. 202 Chirinos, JA, Kips, JG, Jacobs, DR Jr, et al. Arterial wave reflections and incident cardiovascular events and heart failure: MESA (Multiethnic Study of Atherosclerosis). J Am Coll Cardiol 60 (2012), 2170–2177.
203. 203 Shah, SJ, Wasserstrom, JA, Increased arterial wave reflection magnitude: a novel form of stage B heart failure?. J Am Coll Cardiol 60 (2012), 2178–2181.
204. 204 Sung, SH, Yu, WC, Cheng, HM, et al. Excessive wave reflections on admission predict post-discharge events in patients hospitalized due to acute heart failure. Eur J Heart Fail 14 (2012), 1348–1355.
205. 205 Chirinos, JA, Segers, P, Duprez, DA, et al. Late systolic central hypertension as a predictor of incident heart failure: the Multi-ethnic Study of Atherosclerosis. J Am Heart Assoc, 4, 2015, e001335.
206. 206 Wang, KL, Cheng, HM, Sung, SH, et al. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study. Hypertension 55 (2010), 799–805.
207. 207 Weber, T, Wassertheurer, S, Rammer, M, et al. Validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension 58 (2011), 825–832.
208. 208 Hughes, AD, Ahead of the curve: waveform analysis of blood pressure, reflection magnitude, and outcomes. Hypertension 64 (2014), 929–930.
209. 209 Zamani, P, Jacobs, DR Jr, Segers, P, et al. Reflection magnitude as a predictor of mortality: the Multi-Ethnic Study of Atherosclerosis. Hypertension 64 (2014), 958–964.
210. 210 Fadl Elmula, FE, Rebora, P, Talvik, A, et al., the BEtter control of blood pressure in hypertensive pAtients monitored Using the HOTMAN sYstem (BEAUTY) Study Investigators. A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. J Hypertens 33 (2015), 2534–2545.
211. 211 Borch-Johnsen, K, Feldt-Rasmussen, B, Strandgaard, S, Schroll, M, Jensen, JS, Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19 (1999), 1992–1997.
212. 212 Okin, PM, Devereux, RB, Jern, S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 108 (2003), 684–690.
213. 213 Vlachopoulos, C, Xaplanteris, P, Aboyans, V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 241 (2015), 507–532.
214. 214 Bramwell, J, Hill, AY, Velocity of transmission of the pulse-wave and elasticity of arteries. Lancet 199 (1922), 891–892.
215. 215 Laurent, S, Boutouyrie, P, Asmar, R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (2001), 1236–1241.
216. 216 Laurent, S, Cockcroft, J, Van Bortel, L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27 (2006), 2588–2605.
217. 217 Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 31 (2010), 2338–2350.
218. 218 Van Bortel, LM, Laurent, S, Boutouyrie, P, et al. the Artery Society the European Society of Hypertension Working Group on Vascular Structure and Function, the European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 30 (2012), 445–448.
219. 219 Townsend, RR, Wilkinson, IB, Schiffrin, EL, et al., the American Heart Association Council on Hypertension. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension 66 (2015), 698–722.
220. 220 Greve, SV, Blicher, MK, Kruger, R, et al. Estimated carotid-femoral pulse wave velocity has similar predictive value as measured carotid-femoral pulse wave velocity. J Hypertens 34 (2016), 1279–1289.
221. 221 Najjar, SS, Scuteri, A, Shetty, V, et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 51 (2008), 1377–1383.
222. 222 Greve, SV, Blicher, MK, Sehestedt, T, et al. Effective risk stratification in patients with moderate cardiovascular risk using albuminuria and atherosclerotic plaques in the carotid arteries. J Hypertens 33 (2015), 1563–1570.
223. 223 Januzzi, JL, Troughton, R, Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 127 (2013), 500–507.
224. 224 Pyorala, K, De Backer, G, Graham, I, Poole-Wilson, P, Wood, D, Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, The European Atherosclerosis Society and the European Hypertension Society. A short overview for general practitioners. Lijec Vjesn 118 (1996), 220–226 (in Croatian).
225. 225 Daugherty, SL, Powers, JD, Magid, DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125 (2012), 1635–1642.
226. 226 Asayama, K, Sato, A, Ohkubo, T, et al. The association between masked hypertension and waist circumference as an obesity-related anthropometric index for metabolic syndrome: the Ohasama study. Hypertens Res 32 (2009), 438–443.
227. 227 Schillaci, G, Pirro, M, Vaudo, G, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 43 (2004), 1817–1822.
228. 228 Schillaci, G, Pirro, M, Vaudo, G, et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 45 (2005), 1078–1082.
229. 229 Grassi, G, Seravalle, G, Trevano, FQ, et al. Neurogenic abnormalities in masked hypertension. Hypertension 50 (2007), 537–542.
230. 230 Scuteri, A, Najjar, SS, Orru', M, et al. The central arterial burden of the metabolic syndrome is similar in men and women: the SardiNIA Study. Eur Heart J 31 (2010), 602–613.
231. 231 Scuteri, A, Cunha, PG, Rosei, EA, et al., the MARE Consortium. Arterial stiffness and influences of the metabolic syndrome: a cross-countries study. Atherosclerosis 233 (2014), 654–660.
232. 232 Vishram, JK, Borglykke, A, Andreasen, AH, et al., the MORGAM Project. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS One, 9, 2014, e107294.
233. 233 Palagini, L, Bruno, RM, Gemignani, A, Baglioni, C, Ghiadoni, L, Riemann, D, Sleep loss and hypertension: a systematic review. Curr Pharm Des 19 (2013), 2409–2419.
234. 234 Calhoun, DA, Harding, SM, Sleep and hypertension. Chest 138 (2010), 434–443.
235. 235 Bass, J, Turek, FW, Sleepless in America: a pathway to obesity and the metabolic syndrome?. Arch Intern Med 165 (2005), 15–16.
236. 236 Somers, VK, White, DP, Amin, R, et al. the American Heart Association Council for High Blood Pressure Research Professional Education Committee Council on Clinical Cardiology the American Heart Association Stroke Council the American Heart Association Council on Cardiovascular Nursing, the American College of Cardiology Foundation. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 118 (2008), 1080–1111.
237. 237 Mozaffarian, D, Benjamin, EJ, Go, AS, et al., the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–322.
238. 238 Logan, AG, Perlikowski, SM, Mente, A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 19 (2001), 2271–2277.
239. 239 Gami, AS, Howard, DE, Olson, EJ, Somers, VK, Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 352 (2005), 1206–1214.
240. 240 Peppard, PE, Young, T, Palta, M, Skatrud, J, Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342 (2000), 1378–1384.
241. 241 Haentjens, P, Van Meerhaeghe, A, Moscariello, A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 167 (2007), 757–764.
242. 242 Bazzano, LA, Khan, Z, Reynolds, K, He, J, Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 50 (2007), 417–423.
243. 243 Barbe, F, Durán-Cantolla, J, Capote, F, et al., the Spanish Sleep and Breathing Group. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 181 (2010), 718–726.
244. 244 Tasali, E, Ip, MS, Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 5 (2008), 207–217.
245. 245 Pack, AI, Gislason, T, Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis 51 (2009), 434–451.
246. 246 McNicholas, WT, Bonsigore, MR, the Management Committee of EU COST ACTION B26. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29 (2007), 156–178.
247. 247 Chirinos, JA, Gurubhagavatula, I, Teff, K, et al. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med 370 (2014), 2265–2275.
248. 248 Gottlieb, DJ, Punjabi, NM, Mehra, R, et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med 370 (2014), 2276–2285.
249. 249 Chobanian, AV, Bakris, GL, Black, HR, et al. the National Heart Lung Blood Institute Joint National Committee on Prevention Detection Evaluation Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003), 2560–2572.
250. 250 Sinclair, AM, Isles, CG, Brown, I, Cameron, H, Murray, GD, Robertson, JW, Secondary hypertension in a blood pressure clinic. Arch Intern Med 147 (1987), 1289–1293.
251. 251 Anderson, GH Jr, Blakeman, N, Streeten, DH, The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12 (1994), 609–615.
252. 252 Funder, JW, Carey, RM, Mantero, F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101 (2016), 1889–1916.
253. 253 Lenders, JW, Duh, QY, Eisenhofer, G, et al., the Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99 (2014), 1915–1942.
254. 254 Plouin, PF, Amar, L, Dekkers, OM, et al., the Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174 (2016), G1–10.
255. 255 Persu, A, Giavarini, A, Touzé, E, et al., the ESH Working Group Hypertension and the Kidney. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 32 (2014), 1367–1378.
256. 256 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
257. 257 Ji, W, Foo, JN, O'Roak, BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 40 (2008), 592–599.
258. 258 Carty, DM, Schiffer, E, Delles, C, Proteomics in hypertension. J Hum Hypertens 27 (2013), 211–216.
259. 259 Nikolic, SB, Sharman, JE, Adams, MJ, Edwards, LM, Metabolomics in hypertension. J Hypertens 32 (2014), 1159–1169.
260. 260 Lindsey, ML, Mayr, M, Gomes, AV, et al. the American Heart Association Council on Functional Genomics and Translational Biology Council on Cardiovascular Disease in the Young Council on Clinical Cardiology Council on Cardiovascular and Stroke Nursing Council on Hypertension, Stroke Council. Transformative impact of proteomics on cardiovascular health and disease: a Scientific Statement from the American Heart Association. Circulation 132 (2015), 852–872.
261. 261 Pena, MJ, Jankowski, J, Heinze, G, et al. Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens 33 (2015), 2123–2132.
262. 262 Padmanabhan, S, Caulfield, M, Dominiczak, AF, Genetic and molecular aspects of hypertension. Circ Res 116 (2015), 937–959.
263. 263 Collins, R, Peto, R, MacMahon, S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335 (1990), 827–838.
264. 264 Staessen, JA, Gasowski, J, Wang, JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355 (2000), 865–872.
265. 265 Thomopoulos, C, Parati, G, Zanchetti, A, Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 32 (2014), 2285–2295.
266. 266 Ettehad, D, Emdin, CA, Kiran, A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
267. 267 Patel, A, ADVANCE Collaborative Group, MacMahon, S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
268. 268 Brunstrom, M, Carlberg, B, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, 2016, i717.
269. 269 Emdin, CA, Rahimi, K, Neal, B, Callender, T, Perkovic, V, Patel, A, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
270. 270 Thomopoulos, C, Parati, G, Zanchetti, A, Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs—overview and meta-analyses. J Hypertens 33 (2015), 195–211.
271. 271 Thomopoulos, C, Parati, G, Zanchetti, A, Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk—overview and meta-analyses of randomized trials. J Hypertens 32 (2014), 2305–2314.
272. 272 Hansson, L, Hedner, T, Lund-Johansen, P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356 (2000), 359–365.
273. 273 Dahlof, B, Devereux, RB, Kjeldsen, SE, et al., the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 995–1003.
274. 274 Lindholm, LH, Carlberg, B, Samuelsson, O, Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005), 1545–1553.
275. 275 Staessen, JA, Wang, JG, Thijs, L, Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358 (2001), 1305–1315.
276. 276 Leenen, FH, Nwachuku, CE, Black, HR, et al., the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48 (2006), 374–384.
277. 277 Yusuf, S, Teo, KK, Pogue, J, et al., the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
278. 278 McMurray, JJ, Ostergren, J, Swedberg, K, et al., the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003), 767–771.
279. 279 Dahlof, B, Sever, PS, Poulter, NR, et al., the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005), 895–906.
280. 280 Lindholm, LH, Ibsen, H, Borch-Johnsen, K, et al., the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20 (2002), 1879–1886.
281. 281 Jamerson, K, Weber, MA, Bakris, GL, et al., the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008), 2417–2428.
282. 282 Marott, SC, Nielsen, SF, Benn, M, Nordestgaard, BG, Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 35 (2014), 1205–1214.
283. 283 Jafar, TH, Schmid, CH, Landa, M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135 (2001), 73–87.
284. 284 Chalmers, J, Woodward, M, Borghi, C, Manolis, A, Mancia, G, Strategies to meet the need for long-term data. J Hypertens 34 (2016), 1473–1479.
285. 285 Adeloye, D, Basquill, C, Aderemi, AV, Thompson, JY, Obi, FA, An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens 33 (2015), 230–242.
286. 286 Bakris, G, Sarafidis, P, Agarwal, R, Ruilope, L, Review of blood pressure control rates and outcomes. J Am Soc Hypertens 8 (2014), 127–141.
287. 287 Bakris, GL, Sarafidis, PA, Weir, MR, et al., the ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375 (2010), 1173–1181.
288. 288 Gupta, AK, Arshad, S, Poulter, NR, Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55 (2010), 399–407.
289. 289 Ambrosioni, E, Borghi, C, Pharmacoeconomic and cost-benefit aspects. Mancia, G, Grassi, G, Redon, J, (eds.) Manual of hypertension of the European Society of Hypertension, 2nd edn, 2014, CRC Press, Boca Raton, FL.
290. 290 Ordunez, P, Luciani, S, Barojas, A, Fitzgerald, J, Hennis, AJ, A public health approach to hypertension. Lancet, 385, 2015, 1833.
291. 291 Strauch, B, Petrák, O, Zelinka, T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 31 (2013), 2455–2461.
292. 292 Tomaszewski, M, White, C, Patel, P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 100 (2014), 855–861.
293. 293 Yiannakopoulou, EC, Papadopulos, JS, Cokkinos, DV, Mountokalakis, TD, Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 12 (2005), 243–249.
294. 294 Burnier, M, Wuerzner, G, Struijker-Boudier, H, Urquhart, J, Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 62 (2013), 218–225.
295. 295 Corrao, G, Zambon, A, Parodi, A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 26 (2008), 819–824.
296. 296 Mancia, G, Parodi, A, Merlino, L, Corrao, G, Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 29 (2011), 1012–1018.
297. 297 Atreja, A, Bellam, N, Levy, SR, Strategies to enhance patient adherence: making it simple. MedGenMed, 7, 2005, 4.
298. 298 Morgado, M, Rolo, S, Factors influencing medication adherence and hypertension management revisited: recent insights from cancer survivors. Hypertens Res 35 (2012), 894–896.
299. 299 Tedla, YG, Bautista, LE, Drug side effect symptoms and adherence to antihypertensive medication. Am J Hypertens 29 (2016), 772–779.
300. 300 Epstein, BJ, Vogel, K, Palmer, BF, Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67 (2007), 1309–1327.
301. 301 Scuteri, A, Modestino, A, Frattari, A, Di Daniele, N, Tesauro, M, Occurrence of hypotension in older participants. Which 24-hour ABPM parameter better correlate with?. J Gerontol A Biol Sci Med Sci 67 (2012), 804–810.
302. 302 Sanz, G, Fuster, V, Polypill and global cardiovascular health strategies. Semin Thorac Cardiovasc Surg 23 (2011), 24–29.
303. 303 Wald, NJ, Law, MR, A strategy to reduce cardiovascular disease by more than 80%. BMJ, 326, 2003, 1419.
304. 304 Sanz, G, Fuster, V, Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 6 (2009), 101–110.
305. 305 Sever, PS, Dahlof, B, Poulter, NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003), 1149–1158.
306. 306 Yusuf, S, Bosch, J, Dagenais, G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
307. 307 Chrysant, SG, Chrysant, GS, Future of polypill use for the prevention of cardiovascular disease and strokes. Am J Cardiol 114 (2014), 641–645.
308. 308 Julius, S, Nesbitt, SD, Egan, BM, et al., the Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006), 1685–1697.
309. 309 Luders, S, Schrader, J, Berger, J, et al., the PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26 (2008), 1487–1496.
310. 310 McAlister, FA, the Renin Angiotension System Modulator Meta-Analysis Investigators. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J 33 (2012), 505–514.
311. 311 Lewis, JB, Berl, T, Bain, RP, Rohde, RD, Lewis, EJ, the Collaborative Study Group. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 34 (1999), 809–817.
312. 312 Scuffham, P, Chaplin, S, Legood, R, Incidence and costs of unintentional falls in older people in the United Kingdom. J Epidemiol Community Health 57 (2003), 740–744.
313. 313 Rubenstein, LZ, Josephson, KR, Falls and their prevention in elderly people: what does the evidence show?. Med Clin North Am 90 (2006), 807–824.
314. 314 Woolcott, JC, Richardson, KJ, Wiens, MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169 (2009), 1952–1960.
315. 315 Callisaya, ML, Sharman, JE, Close, J, Lord, SR, Srikanth, VK, Greater daily defined dose of antihypertensive medication increases the risk of falls in older people—a population-based study. J Am Geriatr Soc 62 (2014), 1527–1533.
316. 316 Onder, G, Bonassi, S, Abbatecola, AM, et al., the Geriatrics Working Group of the Italian Medicines Agency. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci 69 (2014), 430–437.
317. 317 Chan, KY, Wang, W, Wu, JJ, et al., the Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet 381 (2013), 2016–2023.
318. 318 Wilson, RS, Boyle, PA, Yu, L, et al. Temporal course and pathologic basis of unawareness of memory loss in dementia. Neurology 85 (2015), 984–991.
319. 319 Knopman, D, Boland, LL, Mosley, T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56 (2001), 42–48.
320. 320 Maillard, P, Seshadri, S, Beiser, A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol 11 (2012), 1039–1047.
321. 321 Au, R, Massaro, JM, Wolf, PA, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol 63 (2006), 246–250.
322. 322 Scuteri, A, Brain injury as end-organ damage in hypertension. Lancet Neurol 11 (2012), 1015–1017.
323. 323 Pendlebury, ST, Cuthbertson, FC, Welch, SJ, Mehta, Z, Rothwell, PM, Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke 41 (2010), 1290–1293.
324. 324 Scuteri, A, Wang, H, Pulse wave velocity as a marker of cognitive impairment in the elderly. J Alzheimers Dis 42 (2014), S401–S410.
325. 325 Arbel-Ornath, M, Hudry, E, Eikermann-Haerter, K, et al. Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer's disease mouse models. Acta Neuropathol 126 (2013), 353–364.
326. 326 Iliff, JJ, Wang, M, Zeppenfeld, DM, et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci 33 (2013), 18190–18199.
327. 327 Scuteri, A, Tesauro, M, Guglini, L, Lauro, D, Fini, M, Di Daniele, N, Aortic stiffness and hypotension episodes are associated with impaired cognitive function in older subjects with subjective complaints of memory loss. Int J Cardiol 169 (2013), 371–377.
328. 328 Jones, DW, Hall, JE, Racial and ethnic differences in blood pressure: biology and sociology. Circulation 114 (2006), 2757–2759.
329. 329 Gafane, LF, Schutte, R, Van Rooyen, JM, Schutte, AE, Plasma renin and cardiovascular responses to the cold pressor test differ in black and white populations: The SABPA study. J Hum Hypertens 30 (2016), 346–351.
330. 330 Mason, RP, Kalinowski, L, Jacob, RF, Jacoby, AM, Malinski, T, Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112 (2005), 3795–3801.
331. 331 Ezzati, M, Riboli, E, Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med 369 (2013), 954–964.
332. 332 Aburto, NJ, Hanson, S, Gutierrez, H, Hooper, L, Elliott, P, Cappuccio, FP, Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ, 346, 2013, f1378.
333. 333 Whelton, PK, He, J, Cutler, JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 277 (1997), 1624–1632.
334. 334 Graudal, NA, Hubeck-Graudal, T, Jurgens, G, Effects of low-sodium diet vs high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 25 (2012), 1–15.
335. 335 Pimenta, E, Gaddam, KK, Oparil, S, Aban, I, Husain, S, Dell'Italia, LJ, Calhoun, DA, Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 54 (2009), 475–481.
336. 336 Rohner, A, Ried, K, Sobenin, IA, Bucher, HC, Nordmann, AJ, A systematic review and metaanalysis on the effects of garlic preparations on blood pressure in individuals with hypertension. Am J Hypertens 28 (2015), 414–423.
337. 337 Khalesi, S, Irwin, C, Schubert, M, Flaxseed consumption may reduce blood pressure: a systematic review and meta-analysis of controlled trials. J Nutr 145 (2015), 758–765.
338. 338 Warburton, DE, Charlesworth, S, Ivey, A, Nettlefold, L, Bredin, SS, A systematic review of the evidence for Canada's Physical Activity Guidelines for Adults. Int J Behav Nutr Phys Act, 7, 2010, 39.
339. 339 Shiroma, EJ, Lee, IM, Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 122 (2010), 743–752.
340. 340 Cornelissen, VA, Smart, NA, Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc, 2, 2013, e004473.
341. 341 Carlson, DJ, Dieberg, G, Hess, NC, Millar, PJ, Smart, NA, Isometric exercise training for blood pressure management: a systematic review and meta-analysis. Mayo Clin Proc 89 (2014), 327–334.
342. 342 Fagard, RH, Cornelissen, VA, Effect of exercise on blood pressure control in hypertensive patients. Eur J Cardiovasc Prev Rehabil 14 (2007), 12–17.
343. 343 Sharman, JE, La Gerche, A, Coombes, JS, Exercise and cardiovascular risk in patients with hypertension. Am J Hypertens 28 (2015), 147–158.
344. 344 Boman, K, Gerdts, E, Wachtell, K, et al. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. Eur J Cardiovasc Prev Rehabil 16 (2009), 242–248.
345. 345 Li, J, Zheng, H, Du, HB, et al. The multiple lifestyle modification for patients with prehypertension and hypertension patients: a systematic review protocol. BMJ Open, 4, 2014, e004920.
346. 346 Funder, JW, Carey, RM, Fardella, C, et al., the Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93 (2008), 3266–3281.
347. 347 Trinquart, L, Mounier-Vehier, C, Sapoval, M, Gagnon, N, Plouin, PF, Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension 56 (2010), 525–532.
348. 348 Wheatley, K, Ives, N, Gray, R, et al., the ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361 (2009), 1953–1962.
349. 349 Bax, L, Woittiez, AJ, Kouwenberg, HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med, 150, 2009, 840.
350. 350 Cooper, CJ, Murphy, TP, Cutlip, DE, et al., the CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 (2014), 13–22.
351. 351 Zennaro, MC, Boulkroun, S, Fernandes-Rosa, F, Inherited forms of mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab 29 (2015), 633–645.
352. 352 Favier, J, Amar, L, Gimenez-Roqueplo, AP, Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 11 (2015), 101–111.
353. 353 Hering, D, Schlaich, M, The Role of Central Nervous System Mechanisms in Resistant Hypertension. Curr Hypertens Rep, 17, 2015, 58.
354. 354 Laurent, S, Steckelings, U, New drugs under development for cardiovascular prevention. Nilsson, PM, Olsen, MH, Laurent, S, (eds.) Early vascular aging (EVA): new directions in cardiovascular protection, 1st edn., 2015, Academic Press, Cambridge, MA.
355. 355 Calhoun, DA, Aldosterone and cardiovascular disease: smoke and fire. Circulation 114 (2006), 2572–2574.
356. 356 Hoppe, UC, Brandt, MC, Wachter, R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 6 (2012), 270–276.
357. 357 Heusser, K, Tank, J, Engeli, S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55 (2010), 619–626.
358. 358 Bakris, GL, Nadim, MK, Haller, H, Lovett, EG, Schafer, JE, Bisognano, JD, Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 6 (2012), 152–158.
359. 359 Krum, H, Schlaich, MP, Sobotka, PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383 (2014), 622–629.
360. 360 Esler, MD, Böhm, M, Sievert, H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 35 (2014), 1752–1759.
361. 361 Hering, D, Marusic, P, Walton, AS, et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension 64 (2014), 118–124.
362. 362 Azizi, M, Sapoval, M, Gosse, P, et al., the Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385 (2015), 1957–1965.
363. 363 Bhatt, DL, Kandzari, DE, O'Neill, WW, et al., the SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370 (2014), 1393–1401.
364. 364 Kandzari, DE, Bhatt, DL, Brar, S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 36 (2015), 219–227.
365. 365 Mahfoud, F, Tunev, S, Ewen, S, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 66 (2015), 1766–1775.
366. 366 Hering, D, Marusic, P, Walton, AS, et al. Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension. Int J Cardiol 202 (2016), 388–393.
367. 367 Williams, B, MacDonald, TM, Morant, S, et al., the British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386 (2015), 2059–2068.
368. 368 Li, Q, Youn, JY, Cai, H, Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J Hypertens 33 (2015), 1128–1136.
369. 369 Wenzel, U, Turner, JE, Krebs, C, Kurts, C, Harrison, DG, Ehmke, H, Immune mechanisms in arterial hypertension. J Am Soc Nephrol 27 (2016), 677–686.
370. 370 Titze, J, A different view on sodium balance. Curr Opin Nephrol Hypertens 24 (2015), 14–20.
371. 371 Westerbacka, J, Tamminen, M, Cockcroft, J, Yki-Järvinen, H, Comparison of in vivo effects of nitroglycerin and insulin on the aortic pressure waveform. Eur J Clin Invest 34 (2004), 1–8.
372. 372 Kelly, RP, Gibbs, HH, O'Rourke, MF, et al. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. Eur Heart J 11 (1990), 138–144.
373. 373 Jiang, XJ, O'Rourke, MF, Jin, WQ, et al. Quantification of glyceryl trinitrate effect through analysis of the synthesised ascending aortic pressure waveform. Heart 88 (2002), 143–148.
374. 374 Manisty, CH, Hughes, AD, Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 75 (2013), 79–92.
375. 375 Chen, CH, Ting, CT, Lin, SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 25 (1995), 1034–1041.
376. 376 Asmar, R, Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus. J Renin Angiotensin Aldosterone Syst 2:suppl 2 (2001), S8–11.
377. 377 Borlaug, BA, Olson, TP, Abdelmoneim, SS, et al. A randomized pilot study of aortic waveform guided therapy in chronic heart failure. J Am Heart Assoc, 3, 2014, e000745.
378. 378 Parati, G, Ochoa, JE, Lombardi, C, Bilo, G, Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. Curr Hypertens Rep, 17, 2015, 537.
379. 379 Webb, AJ, Wilson, M, Lovett, N, Paul, N, Fischer, U, Rothwell, PM, Response of day-to-day home blood pressure variability by antihypertensive drug class after transient ischemic attack or nondisabling stroke. Stroke 45 (2014), 2967–2973.
380. 380 Webb, AJ, Fischer, U, Mehta, Z, Rothwell, PM, Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375 (2010), 906–915.
381. 381 Hlatky, MA, Greeland, P, Arnett, DK, et al., the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel marker of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119 (2009), 2343–2349.
382. 382 Fagard, RH, Celis, H, Thijs, L, Wouters, S, Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 54 (2009), 1084–1091.
383. 383 Devereux, RB, Dahlöf, B, Gerdts, E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (2004), 1456–1462.
384. 384 Okin, PM, Devereux, RB, Jern, S, et al., the LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292 (2004), 2343–2349.
385. 385 Devereux, RB, Wachtell, K, Gerdts, E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004), 2350–2356.
386. 386 Olsen, MH, Wachtell, K, Ibsen, H, et al., the LIFE Study Investigators. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 24 (2006), 775–781.
387. 387 Savarese, G, Dei Cas, A, Rosano, G, et al. Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. Int J Cardiol 172 (2014), 403–410.
388. 388 Haller, H, Ito, S, Izzo, JL Jr, et al., the ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364 (2011), 907–917.
389. 389 Wang, TJ, Gona, P, Larson, MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006), 2631–2639.
390. 390 Vermeer, SE, Prins, ND, den Heijer, T, Hofman, A, Koudstaal, PJ, Breteler, MM, Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003), 1215–1222.
391. 391 van Sloten, TT, Sedaghat, S, Laurent, S, et al. Carotid stiffness is associated with incident stroke: a systematic review and individual participant data meta-analysis. J Am Coll Cardiol 66 (2015), 2116–2125.
392. 392 Engelen, L, Bossuyt, J, Ferreira, I, et al., the Reference Values for Arterial Measurements Collaboration. Reference values for local arterial stiffness. Part A: carotid artery. J Hypertens 33 (2015), 1981–1996.
393. 393 Ait-Oufella, H, Collin, C, Bozec, E, et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. J Hypertens 28 (2010), 2336–2341.
394. 394 Laurent, S, Briet, M, Boutouyrie, P, Arterial stiffness as surrogate end point: needed clinical trials. Hypertension 60 (2012), 518–522.
395. 395 Aujoulat, I, Marcolongo, R, Bonadiman, L, Deccache, A, Reconsidering patient empowerment in chronic illness: a critique of models of self-efficacy and bodily control. Soc Sci Med 66 (2008), 1228–1239.
396. 396 Simmons, LA, Wolever, RQ, Bechard, EM, Snyderman, R, Patient engagement as a risk factor in personalized health care: a systematic review of the literature on chronic disease. Genome Med, 6, 2014, 16.
397. 397 Chodosh, J, Morton, SC, Mojica, W, et al. Meta-analysis: chronic disease self-management programs for older adults. Ann Intern Med 143 (2005), 427–438.
398. 398 Kuo, CC, Lin, CC, Tsai, FM, Effectiveness of empowerment-based self-management interventions on patients with chronic metabolic diseases: a systematic review and meta-analysis. Worldviews Evid Based Nurs 11 (2014), 301–315.
399. 399 WHO. Health promotion. Track 1: community empowerment. http://www.who.int/healthpromotion/conferences/7gchp/track1/en/, 2010 (accessed May 10, 2016).
400. 400 The Popular Aid For Relief And Development. Strategy two: community empowerment. http://www.pard-lb.org/en/what-we-do/community-empowerment, 2016 (accessed May 10, 2016).
401. 401 Hartono, B, Empowering the community to fight against hypertension: the Indonesian experience. http://www.searo.who.int/publications/journals/regional_health_forum/rhfv17n1p32.pdf, 2013 (accessed May 10, 2016).
402. 402 CDX & Changes. What is community empowerment?. http://www.iacdglobal.org/files/what_is_community_empowerment.pdf, 2008 (accessed May 10, 2016).
403. 403 Morisky, DE, Levine, DM, Green, LW, Shapiro, S, Russell, RP, Smith, CR, Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health 73 (1983), 153–162.
404. 404 Mattila, R, Malmivaara, A, Kastarinen, M, Kivelä, SL, Nissinen, A, Effectiveness of multidisciplinary lifestyle intervention for hypertension: a randomised controlled trial. J Hum Hypertens 17 (2003), 199–205.
405. 405 Sawicki, PT, Mühlhauser, I, Didjurgeit, U, Berger, M, Improvement of hypertension care by a structured treatment and teaching programme. J Hum Hypertens 7 (1993), 571–573.
406. 406 Iso, H, Shimamoto, T, Yokota, K, Sankai, T, Jacobs, DR Jr, Komachi, Y, Community-based education classes for hypertension control. A 1·5-year randomized controlled trial. Hypertension 27 (1996), 968–974.
407. 407 Wilson, A, Childs, S, The relationship between consultation length, process and outcomes in general practice: a systematic review. Br J Gen Pract 52 (2002), 1012–1020.
408. 408 Johnson, HM, Olson, AG, LaMantia, JN, et al. Documented lifestyle education among young adults with incident hypertension. J Gen Intern Med 30 (2015), 556–564.
409. 409 Ribeiro, CD, Resqueti, VR, Lima, I, Dias, FA, Glynn, L, Fregonezi, GA, Educational interventions for improving control of blood pressure in patients with hypertension: a systematic review protocol. BMJ Open, 5, 2015, e006583.
410. 410 Perk, J, De Backer, G, Gohlke, H, et al. the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), the ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33 (2012), 1635–1701.
411. 411 Stead, LF, Buitrago, D, Preciado, N, Sanchez, G, Hartmann-Boyce, J, Lancaster, T, Physician advice for smoking cessation. Cochrane Database Syst Rev, 5, 2013 CD000165.
412. 412 The World Bank. World development indicators: health systems. http://wdi.worldbank.org/table/2.15, 2015 (accessed Dec 28, 2015).
413. 413 Bauer, UE, Briss, PA, Goodman, RA, Bowman, BA, Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet 384 (2014), 45–52.
414. 414 Jafar, TH, Islam, M, Hatcher, J, et al., the Hypertension Research Group. Community based lifestyle intervention for blood pressure reduction in children and young adults in developing country: cluster randomised controlled trial. BMJ, 340, 2010, c2641.
415. 415 Coleman, R, Gill, G, Wilkinson, D, Noncommunicable disease management in resource-poor settings: a primary care model from rural South Africa. Bull World Health Organ 76 (1998), 633–640.
416. 416 Farzadfar, F, Murray, CJ, Gakidou, E, et al. Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz workers) in Iran: a nationally representative observational study. Lancet 379 (2012), 47–54.
417. 417 Wal, P, Wal, A, Bhandari, A, Pandey, U, Rai, AK, Pharmacist involvement in the patient care improves outcome in hypertension patients. J Res Pharm Pract 2 (2013), 123–129.
418. 418 Carter, BL, Rogers, M, Daly, J, Zheng, S, James, PA, The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med 169 (2009), 1748–1755.
419. 419 Santschi, V, Chiolero, A, Colosimo, AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc, 3, 2014, e000718.
420. 420 Zillich, AJ, Jaynes, HA, Bex, SD, et al. Evaluation of pharmacist care for hypertension in the Veterans Affairs patient-centered medical home: a retrospective case-control study. Am J Med 128 (2015), 539.e1–539.e6.
421. 421 Hess, PL, Reingold, JS, Jones, J, et al. Barbershops as hypertension detection, referral, and follow-up centers for black men. Hypertension 49 (2007), 1040–1046.
422. 422 Victor, RG, Ravenell, JE, Freeman, A, et al. Effectiveness of a barber-based intervention for improving hypertension control in black men: the BARBER-1 study: a cluster randomized trial. Arch Intern Med 171 (2011), 342–350.
423. 423 Aujoulat, I, Jacquemin, P, Rietzschel, E, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract 5 (2014), 141–147.
424. 424 Ward, AM, Heneghan, C, Perera, R, et al. What are the basic self-monitoring components for cardiovascular risk management?. BMC Med Res Methodol, 10, 2010, 105.
425. 425 Fletcher, BR, Hinton, L, Hartmann-Boyce, J, Roberts, NW, Bobrovitz, N, McManus, RJ, Self-monitoring blood pressure in hypertension, patient and provider perspectives: a systematic review and thematic synthesis. Patient Educ Couns 99 (2016), 210–219.
426. 426 McManus, RJ, Mant, J, Roalfe, A, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. BMJ, 331, 2005, 493.
427. 427 Cappuccio, FP, Kerry, SM, Forbes, L, Donald, A, Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ, 329, 2004, 145.
428. 428 Halme, L, Vesalainen, R, Kaaja, M, Kantola, I, the HOme MEasuRement of blood pressure study group. Self-monitoring of blood pressure promotes achievement of blood pressure target in primary health care. Am J Hypertens 18 (2005), 1415–1420.
429. 429 Fletcher, BR, Hartmann-Boyce, J, Hinton, L, McManus, RJ, The effect of self-monitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. Am J Hypertens 28 (2015), 1209–1221.
430. 430 Laine, C, Davidoff, F, Patient-centered medicine. A professional evolution. JAMA 275 (1996), 152–156.
431. 431 Marshall, M, Bibby, J, Supporting patients to make the best decisions. BMJ, 342, 2011, d2117.
432. 432 Keirns, CC, Goold, SD, Patient-centered care and preference-sensitive decision making. JAMA 302 (2009), 1805–1806.
433. 433 Grant, RW, Pandiscio, JC, Pajolek, H, et al. Implementation of a web-based tool for patient medication self-management: the Medication Self-titration Evaluation Programme (Med-STEP) for blood pressure control. Inform Prim Care 20 (2012), 57–67.
434. 434 Bobrie, G, Postel-Vinay, N, Delonca, J, Corvol, P, the SETHI Investigators. Self-measurement and self-titration in hypertension: a pilot telemedicine study. Am J Hypertens 20 (2007), 1314–1320.
435. 435 McManus, RJ, Mant, J, Bray, EP, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 376 (2010), 163–172.
436. 436 Chung, M, Oden, RP, Joyner, BL, Sims, A, Moon, RY, Safe infant sleep recommendations on the Internet: let's Google it. J Pediatr 161 (2012), 1080–1084.
437. 437 Finkelstein, J, Barr, MS, Kothari, PP, Nace, DK, Quinn, M, Patient-centered medical home cyberinfrastructure current and future landscape. Am J Prev Med 40:suppl 2 (2011), S225–S233.
438. 438 Greenhalgh, T, Stramer, K, Bratan, T, Byrne, E, Russell, J, Potts, HW, Adoption and non-adoption of a shared electronic summary record in England: a mixed-method case study. BMJ, 340, 2010, c3111.
439. 439 Nolan, RP, Liu, S, Payne, AY, E-counseling as an emerging preventive strategy for hypertension. Curr Opin Cardiol 29 (2014), 319–323.
440. 440 Liu, S, Dunford, SD, Leung, YW, et al. Reducing blood pressure with Internet-based interventions: a meta-analysis. Can J Cardiol 29 (2013), 613–621.
441. 441 Logan, AG, Transforming hypertension management using mobile health technology for telemonitoring and self-care support. Can J Cardiol 29 (2013), 579–585.
442. 442 Logan, AG, Community hypertension programs in the age of mobile technology and social media. Am J Hypertens 27 (2014), 1033–1035.
443. 443 Logan, AG, Irvine, MJ, McIsaac, WJ, et al. Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics. Hypertension 60 (2012), 51–57.
444. 444 Trudel, M, Cafazzo, JA, Hamill, M, et al. A mobile phone based remote patient monitoring system for chronic disease management. Stud Health Technol Inform 129 (2007), 167–171.
445. 445 Piette, JD, Datwani, H, Gaudioso, S, et al. Hypertension management using mobile technology and home blood pressure monitoring: results of a randomized trial in two low/middle-income countries. Telemed J E Health 18 (2012), 613–620.
446. 446 WHO. NCD Global Monitoring Framework. Ensuring progress on noncommunicable diseases in countries. http://www.who.int/nmh/global_monitoring_framework/en/, 2011 (accessed March 14, 2016).
447. 447 WHO. Scaling up action against NCDs: how much will it cost?. http://www.who.int/nmh/publications/cost_of_inaction/en/, 2011 (accessed March 15, 2016).
448. 448 Lim, SS, Gaziano, TA, Gakidou, E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 370 (2007), 2054–2062.
449. 449 Nugent, R, Benefits and costs of the non-communicable disease targets for the post-2015 development agenda. http://www.copenhagenconsensus.com/sites/default/files/health_perspective_ncd_-_nugent.pdf, 2015 (accessed Feb 7, 2016).
450. 450 Barton, P, Andronis, L, Briggs, A, McPherson, K, Capewell, S, Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ, 343, 2011, d4044.
451. 451 Wang, G, Labarthe, D, The cost-effectiveness of interventions designed to reduce sodium intake. J Hypertens 29 (2011), 1693–1699.
452. 452 WHO, World Economic Forum. From burden to “best buys”: reducing the economic impact of NCDs in low- and middle-income countries. http://www.who.int/nmh/publications/best_buys_summary/en/, 2011 (accessed Feb 7, 2016).
453. 453 WHO. Health systems strategy. http://www.who.int/healthsystems/strategy/en/, 2007 (accessed March 15, 2016).
454. 454 Sweeney, S, Obure, CD, Maier, CB, Greener, R, Dehne, K, Vassall, A, Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience. Sex Transm Infect 88 (2012), 85–99.
455. 455 Angell, SY, De Cock, KM, Frieden, TR, A public health approach to global management of hypertension. Lancet 385 (2015), 825–827.
456. 456 WHO. Innovative care for chronic conditions: building blocks for action. http://www.who.int/chp/knowledge/publications/icccreport/en/, 2002 (accessed March 15, 2016).
457. 457 Coleman, K, Austin, BT, Brach, C, Wagner, EH, Evidence on the chronic care model in the new millennium. Health Aff (Millwood) 28 (2009), 75–85.
458. 458 Jaffe, MG, Lee, GA, Young, JD, Sidney, S, Go, AS, Improved blood pressure control associated with a large-scale hypertension program. JAMA 310 (2013), 699–705.
459. 459 Pan American Health Organization. PAHO Strategic Fund. http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=1159&Itemid=452&lang=en, 2014 (accessed March 15, 2016).
460. 460 WHO. Universal health coverage. http://www.who.int/healthsystems/universal_health_coverage/en/, 2014 (accessed March 15, 2016).
461. 461 Dalton, AR, Universal health insurance—a prerequisite of a 21st century health system: the case for hypertension management. Future Cardiol 10 (2014), 327–331.
462. 462 Mathauer, I, Theisling, M, Mathivet, B, Vilcu, I, State budget transfers to health insurance funds: extending universal health coverage in low- and middle-income countries of the WHO European Region. Int J Equity Health, 15, 2016, 27.
463. 463 Feng, XL, Pang, M, Beard, J, Health system strengthening and hypertension awareness, treatment and control: data from the China Health and Retirement Longitudinal Study. Bull World Health Organ 92 (2014), 29–41.
464. 464 German, RR, Lee, LM, Horan, JM, Milstein, RL, Pertowski, CA, Waller, MN, for the Guidelines Working Group Centers for Disease Control and Prevention (CDC). Updated guidelines for evaluating public health surveillance systems: recommendations from the Guidelines Working Group. MMWR Recomm Rep 50:RR-13 (2001), 1–35.
465. 465 Mackenbach, JP, McKee, M, A comparative analysis of health policy performance in 43 European countries. Eur J Public Health 23 (2013), 195–201.
466. 466 Centers for Disease Control and Prevention. Centers for Medicare & Medicaid Services. Million hearts. http://millionhearts.hhs.gov/about-million-hearts/index.html, 2016 (accessed March 15, 2016).
467. 467 Wright, JS, Wall, HK, Briss, PA, Schooley, M, Million hearts—where population health and clinical practice intersect. Circ Cardiovasc Qual Outcomes 5 (2012), 589–591.
468. 468 Bi, Z, Liang, X, Xu, A, et al. Hypertension prevalence, awareness, treatment, and control and sodium intake in Shandong Province, China: baseline results from Shandong-Ministry of Health Action on Salt Reduction and Hypertension (SMASH), 2011. Prev Chronic Dis, 11, 2014, EE8.
469. 469 Chen, X, Guo, X, Ma, J, et al. Urinary sodium or potassium excretion and blood pressure in adults of Shandong province, China: preliminary results of the SMASH project. J Am Soc Hypertens 9 (2015), 754–762.
470. 470 Centers for Disease Control and Prevention. Global NCD, injury, and environmental health. Sodium reduction and hypertension: controlling the ‘silent killer’. http://www.cdc.gov/globalhealth/healthprotection/ncd/pdf/factsheets/ncd_sodium_reduction_hypertension_01-2016.pdf, 2016 (accessed March 3, 2016).
471. 471 Vasan, RS, Beiser, A, Seshadri, S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 287 (2002), 1003–1010.
472. 472 Wiktor, S, Ford, N, Ball, A, Hirnschall, G, HIV and HCV: distinct infections with important overlapping challenges. J Int AIDS Soc, 17, 2014, 19323.
473. 473 Frieden, TR, Six components necessary for effective public health program implementation. Am J Public Health 104 (2014), 17–22.